18 December 2012

 New technology from Smith & Nephew offers more efficient uterine fibroid removal

Smith & Nephew (LSE:SN NYSE:SNN), the global medical technology business, today introduced the newest addition to its innovative TRUCLEAR◊ System, the TRUCLEAR ULTRA Reciprocating Morcellator 4.0. Designed specifically for removing uterine fibroids, a health issue that will impact an estimated 80% of womeni , this new device provides surgeons with a fast, efficient solution for a hysteroscopic procedure that can help patients avoid the possibility of a hysterectomy, or surgical removal of the uterus.

With a precision-engineered cutting edge and a uniquely designed tip that allows surgeons to access harder-to-reach fibroids, the TRUCLEAR ULTRA Reciprocating Morcellator 4.0 offers a resection rate more than twice that of the leading competitor (laboratory testing on analog tissueii). Also, because TRUCLEAR ULTRA removes fibroids through hysteroscopic morcellation, or mechanical cutting, it requires no incisions or electrical energy to be used in the uterus and can be performed as an outpatient procedure.
“With the TRUCLEAR System, I have the confidence to safely and effectively resect submucosal fibroids and endometrial polyps under constant visualization,” says David A. Stone, M.D., FACOG, who practices in metropolitan Detroit. “While using the TRUCLEAR ULTRA, I was able to remove a 2.5 centimeter diameter submucosal fibroid in a matter of a few minutes. Using this system can help preserve a woman's future fertility by minimizing damage to the uterus.”

Uterine fibroids are estimated to cost the U.S. healthcare system over $6 billion every yeariii. The most common surgical recommendation for these non-cancerous growths is to remove the uterus through a hysterectomy. For women, a hysterectomy means a hospital stay, four to eight weeks of recovery time, the added risk of infection, and the potential for long-term physical and psychological effects.

“Fibroids are one of the most significant diseases that women face,” explains Mira Sahney, General Manager, Gynecology for Smith & Nephew. “Our new device offers a woman with uterine fibroids a considerably less invasive treatment option that may help preserve her ability to have children.”

Smith & Nephew has a growing presence in the market to provide women with less-invasive treatment options for uterine care. The company continues to innovate in this area and provides surgeons with options for performing polypectomies and myomectomies safely and effectively under continuous, clear visualization.

-  ends -


Brad Merrick     
Smith & Nephew     
(901) 399-1089      

Phil Cowdy
Smith & Nephew
44 (0)20 7401 7646

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion.  Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.

Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.

◊ Trademark of Smith & Nephew. Registered US Patent and Trademark Office.


i US Dept. of Health and Human Services Office on Woman’s Health: Uterine fibroids fact sheet, http://www.womenshealth.gov/publications/our-publications/fact-sheet/uterine-fibroids.cfm

ii Data on file with Smith & Nephew 2012, Reference 15001615.

iii James Segars, M.D., et.al.; Dec. 20, 2011, American Journal of Obstetrics and Gynecology online